Dividend
-
-
-
-
-
-
-
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
-
-
-
-
-
-
-
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
-
-
-
-
-
-
-
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
-
-
-
-
-
-
-
QIAGEN Announces Plans to Return Approximately $250 Million to Shareholders Via Synthetic Share Repurchase Proposal
445,815 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

